Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomarkers, Not DSM, Needed To Speed Diagnostics, Drug Development For Brain Disorders

This article was originally published in The Pink Sheet Daily

Executive Summary

Diagnosing and treating brain disorders relies too much on subjective factors. But there are efforts brewing to turn that approach on its head, and move toward better biomarker-based diagnostics, according to the Broad Institute’s Steven Hyman, former head of the National Institute of Mental Health.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel